DE60331049D1 - Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden - Google Patents
Konjugate von zytotoxischen mitteln und biologisch aktiven peptidenInfo
- Publication number
- DE60331049D1 DE60331049D1 DE60331049T DE60331049T DE60331049D1 DE 60331049 D1 DE60331049 D1 DE 60331049D1 DE 60331049 T DE60331049 T DE 60331049T DE 60331049 T DE60331049 T DE 60331049T DE 60331049 D1 DE60331049 D1 DE 60331049D1
- Authority
- DE
- Germany
- Prior art keywords
- biologically active
- conjugates
- cytotoxic agents
- active peptides
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36083102P | 2002-03-01 | 2002-03-01 | |
PCT/US2003/006657 WO2003074551A2 (en) | 2002-03-01 | 2003-03-03 | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60331049D1 true DE60331049D1 (de) | 2010-03-11 |
Family
ID=27789031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60331049T Expired - Lifetime DE60331049D1 (de) | 2002-03-01 | 2003-03-03 | Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden |
Country Status (21)
Country | Link |
---|---|
US (2) | US7771727B2 (de) |
EP (1) | EP1487493B1 (de) |
JP (1) | JP4477881B2 (de) |
KR (1) | KR101003622B1 (de) |
CN (2) | CN102133407A (de) |
AT (1) | ATE455561T1 (de) |
AU (1) | AU2003220011B2 (de) |
BR (1) | BR0308090A (de) |
CA (1) | CA2476182A1 (de) |
CO (1) | CO5611160A2 (de) |
DE (1) | DE60331049D1 (de) |
DK (1) | DK1487493T3 (de) |
ES (1) | ES2339934T3 (de) |
IL (1) | IL163573A0 (de) |
IS (1) | IS7431A (de) |
MX (1) | MXPA04008419A (de) |
NO (1) | NO20044039L (de) |
NZ (1) | NZ534719A (de) |
PL (1) | PL373567A1 (de) |
WO (1) | WO2003074551A2 (de) |
ZA (1) | ZA200406614B (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
PL1604687T3 (pl) * | 2003-03-20 | 2011-04-29 | Nippon Kayaku Kk | Preparat micelarny zawierający słabo rozpuszczalny w wodzie lek przeciwnowotworowy oraz nowy kopolimer blokowy |
WO2004083432A1 (en) * | 2003-03-21 | 2004-09-30 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
KR20070108953A (ko) * | 2003-04-22 | 2007-11-13 | 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. | 펩타이드 벡터 |
US20060281897A1 (en) * | 2003-08-22 | 2006-12-14 | Andre Trouet | Potentialization of the activation of high molecular weight prodrugs |
WO2005041865A2 (en) | 2003-10-21 | 2005-05-12 | Igf Oncology, Llc | Compounds and method for treating cancer |
US9011880B2 (en) | 2003-10-21 | 2015-04-21 | Igf Oncology, Llc | Compounds and methods for treating cancer |
WO2006033296A1 (ja) | 2004-09-22 | 2006-03-30 | Nippon Kayaku Kabushiki Kaisha | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 |
CA2582552A1 (en) | 2004-10-21 | 2006-05-04 | Igf Oncology, Llc | Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer |
US8067376B2 (en) * | 2004-11-03 | 2011-11-29 | Forhumantech Co., Ltd. | Pharmaceutical compositions for transdermal delivery |
WO2007021674A2 (en) * | 2005-08-09 | 2007-02-22 | Millennium Pharmaceuticals, Inc. | Method of acylating maytansinol with chiral amino acids |
WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
US8940332B2 (en) * | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
EP1857548A1 (de) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Mittel und Verfahren zur Induktion von Exon-skipping |
JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤/アジュバントとしての、一般式(I):GlXmGn、または一般式(II):ClXmCnで表される核酸 |
JP6047270B2 (ja) * | 2006-08-11 | 2016-12-21 | バイオマリン テクノロジーズ ベー.フェー. | Dnaリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段 |
US20090239782A1 (en) * | 2006-10-03 | 2009-09-24 | Masaharu Nakamura | High-molecular weight conjugate of resorcinol derivatives |
JP5706157B2 (ja) * | 2007-07-12 | 2015-04-22 | プロセンサ テクノロジーズ ビー.ブイ.Prosensa Technologies B.V. | 化合物を種々の選択臓器又は組織に標的化するための分子 |
CN101790385A (zh) | 2007-07-12 | 2010-07-28 | 普罗森那技术公司 | 用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子 |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
CA2704049A1 (en) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
DK2176408T5 (en) | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
CA2714120A1 (en) | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
CN101977631A (zh) * | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
JP5366940B2 (ja) | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
EP2119783A1 (de) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
CN101439182B (zh) * | 2008-12-18 | 2012-02-01 | 北京大学 | 一种生长抑素受体介导的肿瘤靶向药物组合物 |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
EP2421971B1 (de) | 2009-04-24 | 2016-07-06 | BioMarin Technologies B.V. | Oligonukleotid mit einem inosin zur behandlung von dmd |
WO2010131675A1 (ja) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011078672A1 (en) | 2009-12-24 | 2011-06-30 | Prosensa Technologies B.V. | Molecule for treating an inflammatory disorder |
CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
TW201304805A (zh) | 2010-11-17 | 2013-02-01 | Nippon Kayaku Kk | 新穎之胞核苷系代謝拮抗劑之高分子衍生物 |
CA2824143C (en) | 2011-01-14 | 2018-12-18 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
CN103501823B (zh) | 2011-02-17 | 2018-05-04 | 杜兰教育基金委员会 | 多组分组合物以及它们的用途 |
KR101849142B1 (ko) | 2011-09-11 | 2018-04-16 | 니폰 가야꾸 가부시끼가이샤 | 블록 공중합체의 제조방법 |
EP2806900B1 (de) | 2012-01-27 | 2021-12-15 | BioMarin Technologies B.V. | Rna-modulierende oligonukleotide mit verbesserten eigenschaften zur behandlung der duchenne- und becker-muskeldystrophie |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
KR20150006000A (ko) | 2012-05-01 | 2015-01-15 | 제넨테크, 인크. | 항-pmel17 항체 및 면역접합체 |
EP2850059A4 (de) * | 2012-05-15 | 2016-06-29 | Concortis Biosystems Corp | Wirkstoffkonjugate, konjugationsverfahren und verwendungen davon |
MX2015011348A (es) * | 2013-03-15 | 2016-01-15 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
CN105473158B (zh) | 2013-08-21 | 2021-04-13 | 库瑞瓦格股份公司 | 呼吸道合胞病毒(rsv)疫苗 |
WO2015106224A2 (en) | 2014-01-12 | 2015-07-16 | Hugh Mctavish | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
CN105198966B (zh) * | 2014-06-26 | 2019-06-21 | 中国人民解放军军事医学科学院毒物药物研究所 | GnRH类似物-细胞毒分子缀合物、其制备方法及用途 |
CA2953371C (en) | 2014-06-30 | 2021-08-24 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
US11633487B2 (en) * | 2014-08-06 | 2023-04-25 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
US11643439B2 (en) | 2015-08-05 | 2023-05-09 | Shaanxi Micot Technology Limited Company | Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof |
CN106466485B (zh) * | 2015-08-11 | 2021-05-04 | 同宜医药(苏州)有限公司 | 一种具有细胞内吞介导功能的靶向配体-药物偶联体 |
CA3001712A1 (en) | 2015-10-28 | 2017-05-04 | Tarveda Therapeutics, Inc. | Sstr-targeted conjugates and particles and formulations thereof |
AU2017238246B2 (en) | 2016-03-24 | 2021-04-01 | The Administrators Of The Tulane Educational Fund | Conjugates of tacrolimus, their compositions, and their uses |
CA3019398A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
CN106492226A (zh) * | 2016-10-13 | 2017-03-15 | 武汉大学苏州研究院 | 肿瘤靶向性多肽—蒽环类衍生物 |
AU2018273370A1 (en) | 2017-05-21 | 2019-10-31 | Igf Oncology, Llc | An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome |
WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
WO2019040367A1 (en) * | 2017-08-19 | 2019-02-28 | Ohio State Innovation Foundation | NEW CANCER IMAGING AGENTS BASED ON PEPTIDES |
CN110357947B (zh) * | 2019-03-08 | 2023-05-26 | 南京恒远科技开发有限公司 | 一种combretastatin A4衍生物 |
TW202116356A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩三號公司 | 作為治療劑之微管靶向藥劑之肽結合物 |
TW202116778A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩二號公司 | 作為治療劑之細胞毒素之肽結合物 |
RU2727924C1 (ru) * | 2019-08-20 | 2020-07-27 | Открытое акционерное общество "Всероссийский научный центр молекулярной диагностики и лечения" (ОАО "ВНЦМДЛ") | Высокоэффективный способ получения лекарственной формы адресного действия для терапии злокачественных новообразований |
JP2024521316A (ja) * | 2021-06-09 | 2024-05-31 | クリネティックス ファーマシューティカルズ,インク. | 非ペプチド標的治療薬及びその使用 |
WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
KR20240082935A (ko) * | 2022-12-02 | 2024-06-11 | 성균관대학교산학협력단 | 광화학적 전환 가능한 펩티드-소분자 복합체 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5663306A (en) * | 1984-08-09 | 1997-09-02 | Chiron Corporation | Method of conjugating an activated ester to an amine-containing biological material |
US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
US4812590A (en) | 1987-06-25 | 1989-03-14 | Merck & Co., Inc. | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma |
US5073541A (en) | 1987-11-18 | 1991-12-17 | Administrators Of The Tulane Educational Fund | Treatment of small cell lung cancer with somatostatin analogs |
US5753627A (en) | 1988-12-05 | 1998-05-19 | Novartis Ag | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
US5633263A (en) | 1989-04-26 | 1997-05-27 | The Administrators Of The Tulane Educational Fund | Linear somatostatin analogs |
ES2070329T3 (es) | 1989-07-20 | 1995-06-01 | Sandoz Ltd | Derivados de polipeptidos. |
US5443815A (en) | 1991-11-27 | 1995-08-22 | Diatech, Inc. | Technetium-99m labeled peptides for imaging |
US5411943A (en) | 1992-02-25 | 1995-05-02 | Biomeasure, Inc. | Hepatoma treatment with somatostatin analogs |
US5620675A (en) | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US5597894A (en) | 1995-06-05 | 1997-01-28 | The Louisiana State University Medical Center Foundation | Multi-tyrosinated somatostatin analogs |
US5770687A (en) | 1995-06-07 | 1998-06-23 | Peptor Limited | Comformationally constrained backbone cyclized somatostatin analogs |
US6051554A (en) | 1995-06-07 | 2000-04-18 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
US5708135A (en) | 1995-09-29 | 1998-01-13 | Biomeasure Incorporated | Cyclic peptide analogs of somatostatin |
US5750499A (en) | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
US5843903A (en) | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
US6156725A (en) | 1996-08-16 | 2000-12-05 | National Institute Of Immunology | Drug for the treatment of cancer |
US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US5919934A (en) * | 1997-02-19 | 1999-07-06 | The George Washington University | Compounds, compositions, and methods for cancer imaging and therapy |
JP2002506424A (ja) | 1997-04-22 | 2002-02-26 | キュレイター オブ ザ ユニバーシィティ オブ ミズーリ | ガストリン受容体−親和性ペプチド結合体 |
US6465613B1 (en) | 1998-11-19 | 2002-10-15 | Tulane University | Hydrophilic somatostatin analogs |
AU1607501A (en) | 1999-11-15 | 2001-05-30 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
AU4267700A (en) | 2000-01-13 | 2001-07-19 | Academia Sinica | Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells |
US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
KR20040047846A (ko) | 2001-09-21 | 2004-06-05 | 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드 | 진단 또는 치료용 소마토스타틴 또는 봄베신 유사체콘쥬게이트 및 이들의 용도 |
-
2003
- 2003-03-03 US US10/506,223 patent/US7771727B2/en not_active Expired - Fee Related
- 2003-03-03 DE DE60331049T patent/DE60331049D1/de not_active Expired - Lifetime
- 2003-03-03 NZ NZ534719A patent/NZ534719A/en not_active IP Right Cessation
- 2003-03-03 EP EP03716299A patent/EP1487493B1/de not_active Expired - Lifetime
- 2003-03-03 KR KR1020047013597A patent/KR101003622B1/ko not_active IP Right Cessation
- 2003-03-03 DK DK03716299.7T patent/DK1487493T3/da active
- 2003-03-03 ES ES03716299T patent/ES2339934T3/es not_active Expired - Lifetime
- 2003-03-03 CA CA002476182A patent/CA2476182A1/en not_active Abandoned
- 2003-03-03 BR BRPI0308090-0A patent/BR0308090A/pt not_active IP Right Cessation
- 2003-03-03 JP JP2003573017A patent/JP4477881B2/ja not_active Expired - Lifetime
- 2003-03-03 PL PL03373567A patent/PL373567A1/xx not_active Application Discontinuation
- 2003-03-03 AT AT03716299T patent/ATE455561T1/de active
- 2003-03-03 AU AU2003220011A patent/AU2003220011B2/en not_active Ceased
- 2003-03-03 CN CN2010106215969A patent/CN102133407A/zh active Pending
- 2003-03-03 CN CNA038099276A patent/CN1649625A/zh active Pending
- 2003-03-03 IL IL16357303A patent/IL163573A0/xx unknown
- 2003-03-03 WO PCT/US2003/006657 patent/WO2003074551A2/en active Application Filing
- 2003-03-03 MX MXPA04008419A patent/MXPA04008419A/es active IP Right Grant
-
2004
- 2004-08-19 ZA ZA200406614A patent/ZA200406614B/en unknown
- 2004-08-31 IS IS7431A patent/IS7431A/is unknown
- 2004-09-24 NO NO20044039A patent/NO20044039L/no not_active Application Discontinuation
- 2004-09-29 CO CO04097209A patent/CO5611160A2/es not_active Application Discontinuation
-
2009
- 2009-08-25 US US12/547,096 patent/US20090324620A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR101003622B1 (ko) | 2010-12-24 |
US20060009622A1 (en) | 2006-01-12 |
AU2003220011B2 (en) | 2008-05-29 |
WO2003074551A3 (en) | 2004-03-25 |
BR0308090A (pt) | 2006-04-11 |
ES2339934T3 (es) | 2010-05-27 |
NZ534719A (en) | 2008-02-29 |
EP1487493B1 (de) | 2010-01-20 |
IS7431A (is) | 2004-08-31 |
ZA200406614B (en) | 2006-06-28 |
WO2003074551A2 (en) | 2003-09-12 |
MXPA04008419A (es) | 2004-11-26 |
US20090324620A1 (en) | 2009-12-31 |
CA2476182A1 (en) | 2003-09-12 |
CN1649625A (zh) | 2005-08-03 |
ATE455561T1 (de) | 2010-02-15 |
CN102133407A (zh) | 2011-07-27 |
NO20044039L (no) | 2004-09-29 |
EP1487493A4 (de) | 2006-08-30 |
JP4477881B2 (ja) | 2010-06-09 |
WO2003074551A8 (en) | 2005-11-03 |
IL163573A0 (en) | 2005-12-18 |
DK1487493T3 (da) | 2010-05-25 |
CO5611160A2 (es) | 2006-02-28 |
US7771727B2 (en) | 2010-08-10 |
KR20040088568A (ko) | 2004-10-16 |
JP2006510571A (ja) | 2006-03-30 |
PL373567A1 (en) | 2005-09-05 |
AU2003220011A1 (en) | 2003-09-16 |
EP1487493A2 (de) | 2004-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60331049D1 (de) | Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden | |
YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
DE60239707D1 (de) | Antimikrobielle kationische peptide und diese enthaltende formulierungen | |
PL377553A1 (pl) | Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów | |
CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
BR0107691A (pt) | Sapogeninas substituìdas e seu uso | |
ATE342097T1 (de) | Elektroaktive pore | |
TR200301846T2 (tr) | Cripto bloke edici Antikorlar ve bu antikorların kullanımları. | |
CY1104983T1 (el) | Αντινεοπλασματικοι συνδυασμοι | |
MXPA03010085A (es) | Composiciones y su uso en la hiperplasia. | |
DE60237162D1 (de) | Liposomenladung mit metallionen | |
CY1105225T1 (el) | Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας | |
BR9916857A (pt) | 4 heteroaril diarilaminas | |
DK1329458T3 (da) | Peptider som sænker blodglucoseniveauer | |
BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
NO20055838L (no) | Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav | |
DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
SE9904377D0 (sv) | Pharmaceutical combinations | |
SG149872A1 (en) | Antagonists of the bradykinin b1 receptor | |
NO20073914L (no) | Biologisk aktive peptider | |
HUP0204208A2 (hu) | Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény | |
NO20005548L (no) | Mykobakterieinhibitorer | |
ATE506433T1 (de) | Prozessierung von peptiden und proteinen | |
CY1114651T1 (el) | Φαρμακευτικο σκευασμα που περιλαμβανει β-καρβολινη και η χρηση του για τη θεραπεια της σεξουαλικης δυσλειτουργιας | |
ITFI20030238A1 (it) | Peptidi ciclici antagonisti dell'urotensina-ii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |